Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis.
Enoyl acyl carrier protein (ACP) reductase
InhA inhibitors
Isatin
Molecular docking
Molecular dynamics
Molecular hybridization
Mycobacterium tuberculosis
Pyrimidine
Journal
Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
13
02
2023
revised:
20
04
2023
accepted:
02
05
2023
medline:
10
7
2023
pubmed:
19
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Tuberculosis is a worldwide problem that impose a burden on the economy due to continuous development of resistant strains. The development of new antitubercular drugs is a need and can be achieved through inhibition of druggable targets. Mycobacterium tuberculosis enoyl acyl carrier protein (ACP) reductase (InhA) is an important enzyme for Mycobacterium tuberculosis survival. In this study, we report the synthesis of isatin derivatives that could treat TB through inhibition of this enzyme. Compound 4l showed IC
Identifiants
pubmed: 37201321
pii: S0045-2068(23)00252-3
doi: 10.1016/j.bioorg.2023.106591
pii:
doi:
Substances chimiques
Acyl Carrier Protein
0
Isatin
82X95S7M06
Oxidoreductases
EC 1.-
Antitubercular Agents
0
Pyrimidines
0
Bacterial Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106591Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.